RxDoctor Payments Data

Avelina Coleman

Family · Las Vegas, NVNPI 1720454374

Payments from drug & device makers

$1,376in general payments, 2019–2025

Across 29 payments — averaging $47.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$298
  • Novo Nordisk$287
  • Abbott$254
  • Edwards Lifesciences$131
  • E.r. Squibb & Sons, L.L.C.$118
  • Cvrx, Inc.$98
  • plus $190 from 3 others

What the payments were for

  • Food & beverage$1,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,376 in reported general payments places this provider in the 75th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$5,828
Medicare patients
50
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$16,964
Atorvastatin Calcium136$1,412
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$1,255
Ultra-Fine Short Pen NeedlePen Needle, Diabetic15$882
Gabapentin38$631
Omeprazole46$583
Losartan Potassium75$520
Metformin Hcl56$437
Amlodipine Besylate96$424
Metoprolol Succinate23$339
Lisinopril44$288
Pantoprazole Sodium26$267
Albuterol Sulfate HfaAlbuterol Sulfate13$251
Hydroxyzine Hcl14$242
ClopidogrelClopidogrel Bisulfate21$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$16,96411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →